二肽基肽酶4抑制药改善2型糖尿病视网膜病变的研究现状  被引量:7

Research status of dipeptidyl peptidase 4 inhibitors in improving type 2 diabetic retinopathy

在线阅读下载全文

作  者:朱晓燕 刘勤 白惠玲[3] 张书[3] 刘菊香[4] 张延英[2] ZHU Xiao-yan;LIU Qin;BAI Hui-ling;ZHANG Shu;LIU Ju-xiang;ZHANG Yan-ying(First Clinical Medical School,Gansu University of Chinese Medicine,Lanzhou 730000,Gansu Province,China;Scientific Research and Experiment Center,Gansu University of Chinese Medicine,Lanzhou 730000,Gansu Province,China;Department of Ophthalmology,Gansu Provincial Hospital,Lanzhou 730000,Gansu Province,China;Department of Endocrine,Gansu Provincial Hospital,Lanzhou 730000,Gansu Province,China)

机构地区:[1]甘肃中医药大学第一临床医学院,甘肃兰州730000 [2]甘肃中医药大学科研实验中心,甘肃兰州730000 [3]甘肃省人民医院眼科,甘肃兰州730000 [4]甘肃省人民医院内分泌科,甘肃兰州730000

出  处:《中国临床药理学杂志》2022年第7期739-743,共5页The Chinese Journal of Clinical Pharmacology

基  金:甘肃省卫生行业科研计划基金资助项目(GSWSKY-2019-40);兰州市科技计划基金资助项目(2020-ZD-18)。

摘  要:二肽基肽酶4(DPP-4)抑制药是一类基于肠促胰素的新型口服降糖药物,其还可以通过改善视网膜血管内皮功能、保护血视网膜屏障完整性、预防并减轻视网膜的炎症和氧化应激反应等,从而发挥独特的视网膜保护功能。本文将通过总结DPP-4抑制药治疗2型糖尿病视网膜病变的机制,进而介绍近年来在我国已经上市的5种常见DPP-4抑制药(西格列汀、维格列汀、沙格列汀、阿格列汀、利格列汀)的药代动力学,以及从已批准上市和在研2个方面归纳DPP-4抑制药的临床研究现状,从而较全面地对新型降糖药物DPP-4抑制药改善2型糖尿病视网膜病变的研究现状做一综述。Objective Dipeptidyl peptidase-4(DPP-4) inhibitors were a class of novel oral hypoglycemic drugs based on incretin, which were used to treat type 2 diabetes mainly by promoting insulin secretion, increasing glucose tolerance and reducing insulin resistance. DPP-4 inhibitors also played a protective role in retina, such as improving retinal vascular endothelial function, protecting the integrity of blood retinal barrier, preventing and reducing retinal inflammation and oxidative stress response, etc., which played a unique retinal protective role. In this paper, the pharmacokinetics of 5 common DPP-4 inhibitors(sitagliptin, vigliptin, saxagliptin, alagliptin and ligagliptin) that have been marketed in China in recent years will be introduced by summarizing the mechanism of DPP-4 inhibitors in the treatment of type 2 diabetic retinopathy. In addition, the clinical research status of DPP-4 inhibitors was summarized from the two aspects of approved marketing and in research, so as to comprehensively review the research status of DPP-4 inhibitors in improving type 2 diabetic retinopathy.

关 键 词:二肽基肽酶4抑制药 糖尿病视网膜病变 

分 类 号:R977.15[医药卫生—药品]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象